Rituximab biosimilar is under clinical development by Apotex and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Rituximab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rituximab biosimilar overview

Rituximab biosimilar is under development for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia and follicular lymphoma. It is administered through intravenous route. The drug candidate acts by targeting the B lymphocyte antigen CD20.

Apotex overview

Apotex, a subsidiary of SK Capital Partners LP, develops and manufactures generic pharmaceuticals. The company also offers biosimilars, active pharmaceutical ingredients and consumer products. It carries out the research, development, manufacture, and distribution of non-prescription and private label medicines, fine chemicals, and disposable plastics for medical use. The company serves patients, healthcare providers and payers, governments, and other pharmaceutical manufacturers. The company operates through subsidiaries, joint ventures and licensing agreements across the Americas, Europe, the Middle East, Africa, and Asia Pacific. Apotex is headquartered in Toronto, Ontario, Canada.

For a complete picture of Rituximab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.